Using a broad-beam laser: PTK offers another option for treating chronic flap striae
February 1st 2003Orlando-Phototherapeutic keratectomy (PTK) with a broad-beam laser may be a useful treatment for eyes with chronic, visually significant post-LASIK flap microstriae, said Roger F. Steinert, MD, during the refractive surgery subspecialty day meeting prior to the American Academy of Ophthalmology annual meeting.
Influential position: AAO member named to AMA reimbursement committee
February 1st 2003Here's some good news regarding Medicare reimbursement. American Academy of Ophthalmology (AAO) member William L. Rich III, MD, has been appointed to an influential American Medical Association (AMA) committee on physician reimbursement.
New use permitted: FDA approves latanoprost as first-line IOP reducer
February 1st 2003Peapack, NJ-Pharmacia Ophthalmology will begin making its latanoprost ophthalmic solution(Xalatan) available for initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension.
A comparative study: Ofloxacin found to be effective endophthalmitis prophylaxis
February 1st 2003Salt Lake City-Ofloxacin (Ocuflox, Allergan, Irvine, CA) is more effective for preventing endophthalmitis after cataract surgery compared with ciprofloxacin (Ciloxan, Alcon, Fort Worth, TX), said Randall Olson, MD.
ALT helpful in glaucoma refractory to medical treatment
February 1st 2003Orlando-Argon laser trabeculoplasty (ALT) can achieve substantial IOP reductions in patients with open-angle glaucoma that is refractory to medical therapy. In addition to efficacy, the cost of the procedure compares favorably with medical treatments, which tend to be substantially more costly over time, according to Karen M. Joos, MD, PhD.
Careful preoperative planning: Posterior polar cataract presents multiple surgical challenges
February 1st 2003Orlando-Posterior polar cataract is an invitation to capsule rupture and so cataract surgery in these cases necessitates thorough patient counseling, careful preoperative planning, and adaptations in intraoperative technique, said Samuel Masket, MD.
Managing ocular trauma: Traumatic injury confers ongoing risk for glaucoma development
February 1st 2003Orlando-Periodic IOP monitoring is mandatory in eyes that have sustained a severe injury because they are at significantly increased risk for developing traumatic glaucoma, said Jess T. Whitson, MD.
Low levels of antioxidants may contribute to AMD
February 1st 2003Salt Lake City-Research from the Moran Eye Center, University of Utah School of Medicine, Salt Lake City, showed that low ocular levels of the antioxidants lutein and zeaxanthin could contribute to age-related macular degeneration (AMD).
Customized ablation focus of Nidek workshop
February 1st 2003Orlando-Advancements in refractive surgery were the talk of Nidek's workshop on customized ablation at the American Academy of Ophthalmology (AAO) annual meeting here last fall. The symposium was intended as a forum for ophthalmologists to gain a better understanding of the technology available to them.
Research to Prevent Blindness grants surpass $9.5 million in 2002
February 1st 2003New York-Research to Prevent Blindness (RPB), a voluntary health organization supporting eye research, awarded 94 grants totalling $9.7 million last year for research into the causes, treatment, and prevention of all blinding diseases.
Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy
February 1st 2003New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).
Ruboxistaurin results: Eli Lilly plans more trials
February 1st 2003Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.
International partners: InSite Vision, SIFI take OcuGene test to Italy
February 1st 2003Alameda, CA-InSite Vision Inc. and SIFI (Societa Industria Farmaceutica Italiana), a leading Italian pharmaceutical company, will exclusively manufacture, distribute, and promote the OcuGene genetic glaucoma test in Italy.
Fixed drug combination might offer better trough control
January 15th 2003Orlando-A carefully designed comparison study has shown that the fixed combination of dorzolamide-timolol (Cosopt, Merck) is at least as effective as its concomitant components and might provide better trough control in some patients, said Stanley J. Berke, MD, FACS.
Iris color changes less in eyes treated with unoprostone
January 15th 2003Orlando-The incidence of iris hyperpigmentation associated with unoprostone isopropyl ophthalmic solution 0.15% (Rescula, Novartis) was about 1% in two long-term studies, a rate that compares favorably with the incidence of 10% to 20% associated with latanoprost ophthalmic solution (Xalatan, Pharma-cia) in similar patient populations, reported Bernard E. McCarey, PhD.
IOP-lowering efficacy of bimatoprost, latanoprost weighed
January 15th 2003Bimatoprost 0.03% (Lumigan, Allergan) offers more efficacy than latanoprost 0.005% (Xalatan, Pharmacia) for lowering elevated IOP and is similarly well tolerated, according to the results of a 6-month, multicenter, randomized, double-masked study.
Diurnal studies show benefits of prostaglandin analogues
January 15th 2003Orlando-Although challenging to set up and conduct, studies that check glaucoma patients' IOP at intervals around the clock for 24 hours or longer provide valuable data about the ability of a medication to lower IOP and reduce fluctuation.
SLP holds promise for detection of glaucomatous change
January 15th 2003Orlando-In scanning laser polarimetry (SLP), eye-specific correction of corneal polarization axis and magnitude can be obtained for the quantitative assessmentof the peripapillary retinal nerve fiber lay-er (RNFL) if macular-based strategies are used in eyes free of macular pathology, according to glau-coma specialist David S. Greenfield, MD.
Improved form of brimonidine has fewer contraindications
January 15th 2003Brimonidine tartrate 0.15% (Alphagan P, Allergan) is a "new and improved" version of brimonidine 0.2% (Alphagan, Allergan). It continues to have an efficacy profile similar to the one ophthalmologists have grown used to with brimonidine 0.2%.
Severity of dry eye linked to ablation depth, not flap size
January 15th 2003Fullerton, CA-An analysis of tear film function after LASIK and LASEK indicates patients fared equally in the two groups when LASEK was performed for high myopia.Tear film dysfunction seems to be best correlated to the depth of the ablation and not flap dimension, according to Robert Lingua, MD.
Controlled trial: Topical serum application an effective therapy for bleb oozing
January 15th 2003Orlando-Topical application of autologous serum 20% is effective for fortifying the bleb wall and stopping aqueous oozing, but cessation of the oozing may be associated with an increase in IOP, reported Atsuo Tomidokoro, MD, PhD.